Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Apr 11, 2017

Keywords

ClinConnect Summary

The TRAP-MS clinical trial is studying how different medications can help manage multiple sclerosis (MS) by targeting inflammation in the brain and spinal fluid. Researchers want to find out if changes in specific markers can help predict how well a person with MS will respond to four different drugs, either alone or in combination. This trial is open to adults aged 18 and older who have progressive MS and can walk a little. Participants must also be currently taking an MS medication.

If you decide to join the trial, you will take one of the study drugs and be monitored for up to 18 months. During this time, you'll have regular check-ups that include physical exams and tests to assess your health and the drugs' effects. The goal is to see how well the treatments work and if they can be adjusted based on your individual response. If at any point you experience significant side effects or complete the treatment period, you'll have follow-up calls to check on your health.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Enrolled in 09-I-0032 protocol.
• • Clinically definite MS.
• • Age greater than or equal to 18 years at time of study enrollment.
• • Expanded Disability Status Scale (EDSS) 1.0-7.5.
• • Documented sustained clinical progression of at least 0.5 CombiWISE points/year (measured by greater than or equal to 4 time-points regression analysis of CombiWISE values spanning at least 1.5 years in total).
• • Because currently only NDS utilizes CombiWISE scale, the progression slopes will be determined from NDS protocols: natural history protocol 09-I-0032 or any of the past NDS clinical trials (protocols 09-I-0197, 10-N-0212, 10-N-0125 and 13-I-0088). Consequently, new patients will be screened to this protocol via 09-I-0032 natural history protocol that contains completely overlapping procedures.
• • It is possible that after other MS centers start using CombiWISE scale, this progression criterion may be derived from outside data, as long as they are adequately documented.
• • Subjects of childbearing potential must be willing to use a medically acceptable form of birth control, while being treated on this study.
• • Patients who desire to continue their current FDA-approved DMTs based on its perceived (partial) therapeutic benefit will be enrolled with the understanding that the underlying FDA-approved therapy must remain stable during this protocol. If patient desires and/or his/her medical condition requires changing FDA-approved DMT during the duration of this protocol, the drugs administered under this protocol will be withdrawn, to establish new baseline of CSF biomarkers under changed therapy, and, if necessary, to establish new progression rate. New baseline of CSF biomarkers on changed therapy can be established after 6 months of new therapy. Because the efficacy of current DMTs decreases with patient s age so that on average, zero percent efficacy on disability progression occurs after age 53 (Weideman, Tapia-Maltos et al. 2017), only those patients who change to higher potency therapy (i.e., treatment escalation) before age 53 will need to repeat the entire process of establishing baseline progression rate: go back to greater than or equal to 1.5 year baseline period on new DMT to verify that the rate of progression remains greater than or equal to 0.5 CombiWISE points/year. Following therapeutic change that occurs before age 53 will be considered treatment escalation: 1. Initiation of any FDA-approved DMT in previously untreated subject or 2. Change from any low potency (i.e., copaxone, teriflunomide, interferon beta preparations, dimethyl or monomethyl fumarate and fingolimod) to any high potency drugs (i.e., natalizumab, ocrelizumab, rituximab, alemtuzumab, siponimod, cladribine, ofatumumab, ozanimod, ublituximab and mitoxantrone). All other therapy changes (i.e., parallel change from low efficacy to low efficacy or from high efficacy to high efficacy, as well as discontinuation of treatment after age 53) will require new CSF baseline (6 months after such therapy change), but will not require 18 months to calculate new CombiWISE slope. After new CSF baseline, and, if necessary, new CombiWISE progression slopes are established, patient can be matched to the same monotherapy or combination therapy regimen they were on before the immunomodulatory DMT change.
• • Willing and able to participate in all aspects of the protocol.
• • Able and willing to provide informed consent.
• EXCLUSION CRITERIA:
• • Clinically significant medical disorders that, in the judgment of the investigators, could expose the patient to undue risk of harm or prevent the patient from safely completing all required elements of the study (such as, but not limited to significant cerebrovascular disease, ischemic cardiomyopathy, clotting disorder, other neurodegenerative disorder, substance abuse or significant psychiatric disorder such as depression with suicidal ideations, unable to perform or tolerate MRI examinations).
• • Clinically significant medical disorders, other than MS, that require chronic treatment with immunosuppressive or immunomodulatory agents.
• • Pregnancy or breastfeeding.
• * Abnormal screening/baseline blood tests exceeding any of the limits defined below:
• • Serum alanine transaminase or aspartate transaminase levels which are greater than three times the upper limit of normal values.
• • Total white blood cell count less than 3,000/mm\^3.
• • Platelet count less than 85,000/mm\^3.
• • Serum creatinine level greater than 2.0 mg/dl and eGFR (glomerular filtration rate) less than 60.
• • Serological evidence of HIV, HTLV-1 or active hepatitis A, B or C.
• • Positive pregnancy test.
• • Following drug-specific exclusion criteria will be applied when assigning one of the 4 tested agents (these are not exclusions from the trial)
• • Pioglitazone
• • Congestive heart failure.
• • History of bladder carcinoma.
• • Type 1 diabetes.
• • Hypersensitivity to the drug.
• • Taking teriflunomide (Aubagio) because of risk of hypoglycemia on this combination.
• • Dantrolene
• • Hypersensitivity to the drug.
• • Hepatic impairment/active hepatic disease (cannot be paired with pirfenidone due to risk of cumulative hepatoxicity).
• • Persistent elevation of LFTs.
• • History of previous drug/medication or alcohol-related liver toxicities.
• • Pirfenidone
• • Hypersensitivity to the drug.
• • Hepatic impairment/active hepatic disease (cannot be paired with dantrolene due to risk of cumulative hepatoxicity).
• • Persistent elevation of LFTs.
• • Smoking.